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Abstract
Natural killer cells constitute a phenotypically diverse population
of innate lymphoid cells with a broad functional spectrum.
Classically defined as cytotoxic lymphocytes with the capacity to
eliminate cells lacking self-MHC or expressing markers of stress or
neoplastic transformation, critical roles for NK cells in immunity to
infection in the regulation of immune responses and as vaccine-
induced effector cells have also emerged. A crucial feature of NK
cell biology is their capacity to integrate signals from pathogen-,
tumor- or stress-induced innate pathways and from antigen-
specific immune responses. The extent to which innate and
acquired immune mediators influence NK cell effector function is
influenced by the maturation and differentiation state of the NK
cell compartment; moreover, NK cell differentiation is driven in
part by exposure to infection. Pathogens can thus mould the NK
cell response to maximise their own success and/or minimise the
damage they cause. Here, we review recent evidence that
pathogen- and vaccine-derived signals influence the
differentiation, adaptation and subsequent effector function of
human NK cells.
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HUMAN NK CELL DIFFERENTIATION –
STRAIGHT FROM INNATE TO
ADAPTIVE?
NK cells differentiate from haematopoietic bone
marrow precursors under the influence of innate
cytokines and stromal cell-derived factors and, in
humans, are defined by the expression of CD56,
whilst lacking CD3epsilon. It has been estimated
that there are more than 100 000 distinct NK cell
phenotypes in human peripheral blood alone1;
lymphoid and tissue-resident and migratory NK
cells add to this diversity.2 The distribution of
these different NK cell subsets in the circulation,
their tissue residence or their capacity to home to
different tissues undoubtedly influences their
capacity to respond to damaged, cancerous or
infected cells.
Initial observations pointed to a potential
differentiation pathway for peripheral blood NK
cells in which cells expressing high levels of CD56
were considered as less differentiated precursors of
cells with lower CD56 expression.3 Several
important pieces of evidence support this broad
phenotypic characterisation including the higher
intrinsic proliferative capacity and greater telomere
length of CD56bright NK cells compared to CD56dim
NK cells.4–6 However, any relationship between
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CD56bright and CD56dim NK cells is unlikely to be
direct and the exact relationship remains uncertain.
A recent single-cell transcriptomic analysis
indicated the presence of eight major
differentiation phenotypes of peripheral blood of
NK cells; some of these have the potential to
interconvert in response to cytokine signals whilst
others may represent more terminally
differentiated lineages.7 More recently, cord blood
ILC-1-like precursors were shown to differentiate
into CD56dimKIR+NKG2APeforin+GzB+ NK cells on
OP9 stromal cells in the presence of interleukin (IL)-
2, IL-7 and IL-15.8 However, NK cells derived under
these conditions contained relatively low
frequencies of CD16+ NK cells.8
CD56bright NK cells express high levels of IL-12R,
IL-15R and IL-18R enabling them to respond very
efficiently to these cytokines. CD56dim NK cells
express lower levels of these receptors, instead
expressing markers associated with more advanced
differentiation (CD57), functional education in the
context of HLA-ligands [Killer cell immunoglobulin-
like receptors (KIR)], antibody-dependent
activation (CD16 and CD32) and cytotoxicity
(granzyme B and perforin).9 However, these
different differentiation states do not necessarily
correlate with a cell’s ability to integrate innate or
adaptive signals per se. A subset of CD56bright NK
cells, for example, expresses the high-affinity IL-2
receptor heterodimer (CD25/CD122), responds to
picogram concentrations of IL-2 and interacts with
CD4+ T cells in secondary lymphoid tissues,
suggesting that these cells amplify the responses of
antigen-specific memory T cells.10 However,
CD56dim NK cells that express high levels of FccRIII
(CD16) could be viewed as adapted for integration
of antibody-dependent signals but also acquire the
high-affinity IL-2R on activation.11 Furthermore,
detailed examination of transcription factor and
transmembrane signalling adaptor expression of
human blood NK cells reveals a polarisation of
CD56dim NK cell functional phenotypes from
‘canonical’ cells (expressing the proteomyelocytic
zinc finger (PLZF) molecule) to ‘adaptive’ NK cells
(lacking the expression of this transcription
factor).12,13 Reduced expression of PLZF is
associated with loss of FceR1c and associated
signalling components including Syk and EAT-2 and
alternative signalling via the CD3zeta chain.12,13
Paradoxically, in vitro cross-linking of NKG2C
combined with long-term IL-15 stimulation not
only induces expansion of highly differentiated
‘adaptive’ CD56dimCD57+NKG2C+ NK cells but also
promotes their co-expression of NKG2A and the
checkpoint inhibitors PD1 and LAG3 and induces
trans-differentiation from CD45RA to CD45RO
isoform expression.14 Hence, chronic stimulation
may promote further differentiation of NK cells.
Interestingly, CD56bright NK cells and a subset of
CD56dim NK cells also lack PLZF and FceR1c
suggesting that there is significant plasticity in
signalling pathways across distinct NK cell
differentiation stages.13 In many ways, this
plasticity of NK cell differentiation and adaptation
should not be surprising considering the role of
epigenetic changes in the diversification process.
‘Adaptive’ NK cells undergo gene silencing via
methylation of loci associated with expression and
responsiveness to innate cytokines whereas
demethylation promotes a lower threshold for
activation via alternative pathways including at
the IFN-c locus.13
NK CELL DIFFERENTIATION IS DRIVEN,
IN PART, BY HCMV
The spectrum of NK cell differentiation varies
between individuals reflecting, in part, their prior
infection history.7 Pathogens express immune-
activating molecules (pathogen-associated
molecular patterns) or induce tissue damage-
associated ‘danger’ signals that contribute to NK
cell activation either directly or via cytokines
produced by intermediary ‘accessory’ cells such as
monocytes and macrophages. The phenotypic and
functional repertoire of NK cells responding to a
distinct pathogen, and the magnitude of that
response, will therefore vary according to the
strength and duration of these pathogen-derived
signals.
A role for infection in driving the
differentiation and functional adaptation of
human NK cells is particularly well documented
for human cytomegalovirus (HCMV). Expansions
of NK cells expressing CD57 and NKG2C (a
receptor recognising cognate HLA-E stabilised on
HCMV-infected cells by peptides from the UL40
viral protein) and lacking PLZF and FceR1c are
frequently found in bone marrow transplant
patients experiencing HCMV infection or
reactivation and are elevated in frequency in
HCMV seropositive compared to seronegative
individuals.12 However, expansions of NK cells
lacking FceR1c, EAT-2 and Syk1 but with
intermediate levels of CD57 expression are also
observed in HCMV seronegative individuals,
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highlighting the potential for peripheral NK cell
differentiation to be driven by other
mechanisms.15 The potential for a non-linear,
HCMV-independent pathway for functional NK
cell diversification is further supported by the
observation of dynamic, intra-individual
fluctuations in the frequencies of these cells over
a protracted period of time in HCMV seronegative
individuals.15
HCMV-infected myeloid cells and fibroblasts are
in many ways the archetypic example of
pathogen-induced NK cell activation and
differentiation, both directly via binding of
HCMV-induced ligands on infected host cells to
NK cell surface receptors including NKG2C, LILRB1
and activating KIR and indirectly through the
action of pro-inflammatory cytokines, interleukin-
2 and antibodies emanating from other immune
cells.16,17
Human ‘adaptive’ NK cells (defined by the
expression of NKG2C or loss of PLZF/Fcer1c
associated pathways and induced by cognate
interaction between NKG2C and HLA-E on HCMV-
infected cells) share many features of murine
‘memory’ NK cells induced by binding of the
murine cytomegalovirus (MCMV) m157 protein to
NK Ly49h receptors.18 In both cases, NK cell
expansion and differentiation are supported by
accessory cell secretion of IL-12 and leads to
generation of effector cells with superior killing
activity and control of CMV infection.18,19
Additionally, ‘cytokine-induced-memory-like’
(CIML) NK cells can be generated in vitro in both
humans and mice with combinations of accessory
cytokines (IL-12, IL-18 and IL-15); these cells
respond to subsequent in vitro stimulation by
enhanced cytokine secretion, and this enhanced
activity is retained after adoptive transfer.20,21
CIML NK cells are distinguishable from human
adaptive NK cells and murine memory NK cells in
their lack of specificity for individual pathogens
and their independence from cognate CMV-
NKG2C/Ly49h interactions (reviewed in Pahl
et al.22).
In the ‘real world’ of complex individual
infection histories, these categorisations may be
less clear with adaptive/memory cells acquiring
additional CIML-like properties after in vivo
exposure to acute infection, inflammation or
vaccination. CIML NK cells are likely to be further
expanded and differentiated by subsequent CMV
infection. Nevertheless, the dominant role of
HCMV in promoting the differentiation and
functional adaptation of human NK cells
(especially after infection in early life) has the
potential to directly influence responses to third
party infections. HCMV-associated ‘adaptive’ NK
cells in humans have enhanced capacity for
antibody-mediated activation and killing of
infected target cells (antibody-dependent cellular
cytotoxicity, ADCC)12,13,18 although their long-
term fate during HCMV infection or reactivation
may ultimately depend on the presence or
absence of co-stimulatory signals.
Endemicity of HCMV infection is greatly
influenced by environment, for which
geographical location and ethnicity have been
used as proxies. Generally speaking, HCMV
seroprevalence increases with equatorial
proximity, with the highest prevalence being
reported in sub-Saharan Africa.23 Rates of HCMV
infection in infants and children are also highest
in these settings with between 83% and 98% of
individuals becoming infected by the age of
14 years.23 In a UK population, higher
seroprevalence of HCMV (and, incidentally, herpes
simplex virus, HSV) was observed in children of
Asian heritage than amongst children of white
British heritage raising the possibility that
immune differentiation, and thus disease
susceptibility or presentation, may vary amongst
communities of differing ethnicity within the
same geographical location.24 NK cell
differentiation occurs noticeably more rapidly (i.e.
in younger age groups) in settings of high HCMV
endemicity with, for example, maximal expansion
of CD57+NKG2C+ and CD57+NKG2A+ NK cells
being reached by 10 years of age in an African
population with near universal HCMV infection in
the first year of life.25 This is accompanied by loss
of NK cell responsiveness to innate cytokines but
maintenance of robust antibody-dependent
activation25 and emergence of high frequencies of
‘adaptive’ FceR1cCD56dim NK cells in childhood
and early adulthood.26,27 Similar effects are
observed in temperate areas of the northern
hemisphere, but over a more protracted period,
with advanced NK cell differentiation mostly
occurring later in life in these lower HCMV
seroprevalence settings.28–30
THE ROLE OF OTHER PATHOGENS IN
NK CELL DIFFERENTIATION
Whilst HCMV infection is associated with robust
NK cell differentiation and adaptation, perhaps
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setting the stage for subsequent responses, other
pathogens also influence the expansion and
differentiation of particular NK cell subsets. In
experimental settings, several examples have
emerged of direct activation of NK cells by
binding of pathogen-encoded ligands to either
invariant or polymorphic NK cell receptors. One
recent, well-characterised example is that of a
conserved peptide epitope from bacterial
recombinase A (rec A) that is presented by HLA-
C*0501 and recognised by the human NK cell
receptor KIR2DS4 enabling NK cell activation by
diverse bacteria including Brucella,
Campylobacter, Chlamydia and Helicobacter
species.31 Similarly, a highly conserved epitope in
the helicase of flaviviruses is presented by HLA-
C*0102 and binds to KIR2DS2, inducing NK cell
degranulation and cytotoxicity32 and several HIV-
derived peptides have been identified that either
provoke or inhibit NK cell responses in the
context of KIR-HLA interactions.33,34 By contrast,
the fungal pathogen Aspergillus fumigatus is
reported to bind directly to NK cell CD56,
resulting in NK cell activation, beta chemokine
production and a reduction in CD56 expression.35
Whilst A. fumigatus appears to interact with both
CD56bright and CD56dim NK cell subsets, fungal
activation reportedly affects expression of other
receptors which may be unevenly distributed
across the NK cell differentiation spectrum,
including NKG2D and NKp46.36 Furthermore,
A. fumigatus-derived signals synergise with
indirect, dendritic cell-derived signals to activate,
and prevent exhaustion of, less differentiated NK
cell subsets.37 Direct interaction of influenza A
virus haemagglutinin with NKp46, NTB-A and 2B4
has also been implicated in the direct activation
of NK cells.38
Certain viruses have the capacity to directly
infect human NK cells, with evidence of tropism
for and impact on NK cell differentiation
phenotype. Varicella-Zoster virus (VZV), for
example, targets CD56dim NK cells, resulting in
acquisition of CD57 but, paradoxically, reducing
surface CD16 expression despite the absence of
VZV-specific antibodies in the culture system.39
Less differentiated NK cells can be infected during
chronic active Epstein–Barr virus infection40: EBV-
infected CD56dim NK cells (with
CD2+CCR7CD11a+CD11bNKG2A+NKG2CNKG2D–
CD57 phenotype) exhibit increased STAT1
phosphorylation and Akt activation with
consequences for viral latency.40
Evidence is also accumulating of indirect
changes in NK cell phenotype and function in
people actively infected with a variety of, mostly
viral, infections (summarised in Table 1); potential
points of interaction between distinct pathogens
and different NK cell differentiation subsets are
summarised in Figure 1. In many cases, these
infections seem to augment the effects of
underlying HCMV infection, although data on
HCMV infection are lacking in some studies
(Table 1). For example, many of the effects of
chronic HIV-1 infection on NK cells are
indistinguishable from those associated with
recurrent infection/reactivation of HCMV
including loss of CD56bright cells and emergence of
CD57+NKG2C+FceR1c cells.41–43 Indeed, reversal of
NKG2A/NKG2C frequencies over a 24-month
period of antiretroviral therapy likely reflects
enhanced immune control of HCMV infection.44
Accelerated acquisition of highly differentiated,
‘adaptive’ NK cell phenotypes is observed in HIV-
1-infected individuals in Europe but these effects
are less marked in HIV-1+ Africans amongst whom
NK cell differentiation is typically already well
advanced due to HCMV infection early in life.45
However, persistent untreated HIV-1 infection
further extends NK cell differentiation with
accumulation of CD56 NKG2C+ cells.46 Proteomic
analysis suggests that these cells emerge from a
CD56dim precursor population47 but it as yet
unclear whether their differentiation is driven by
HIV-1 infection itself (with or without HCMV co-
infection), whether opportunistic infections
(including with fungal pathogens such as
A. fumigatus) also drive this NK cell
differentiation,35 or whether the activating signals
are direct (pathogen ligands binding to NK cell
receptors) or indirect (e.g. mediated by
inflammatory cytokines).
Influenza infection is associated with reduced
frequencies of CD56bright NK cells, coincident with
NK cell production of antiviral and inflammatory
cytokines,48 as well as upregulation of
activation/functional markers (CD69, CD38 and
granzyme B) and a tendency for increased
proliferation of both CD56bright and CD56dimCD16+
NK cells.49 Crucially, a small population of
CD49a+CD16CXCR3+ NK cells with potential lung
homing capacity has been identified during acute
influenza infection and equivalent cells isolated
from lung tissue have been shown to have
antiviral activity in vitro.49 Importantly, many of
these influenza-induced phenotypic changes are
2021 | Vol. 10 | e1244
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Table 1. Impacts of active infections on human NK cell differentiation
Pathogen Impact on NK cell differentiation References
Dengue virus Robust proliferation across the differentiation spectrum although CD56bright and less differentiated CD56 NK
cells dominate, emergence of skin homing CLA+ NK cell phenotype
54
Ebola virus Early acute reduction in CD56bright NK cells precedes proliferation of both CD56bright and CD56dim subsets.
Emergence of CD56CD16+ NK cells persisting after EVD recovery
69,71
Hantavirus IL-15 and HLA-E dependent expansions of CD57+NKG2C+ NK cells. High proportion of HCMV co-infected
individuals
52
Hepatitis C virus Redistribution of CD56bright and CD56dim cell subsets in both acute infection and self-resolving infections.
Reduced CD56dim NK cell frequencies and expansion of CD56CD16+ NK cells. Expansion of CD57+PD-1+ NK
cells. HCMV co-infection not reported
55,56,58
HIV-1 Reduced frequencies of CD56bright and expansion of CD56dimCD57+NKG2C+ NK cells and adaptive NK cells in
chronic infection. Increased frequencies of CD56CD16+ NK cells. Partial resolution after treatment. Likely
role of HCMV co-infection
41–46
Influenza virus Acute infection is associated with reduced CD56bright NK cell frequencies. Activation and proliferation across
the NK cell differentiation spectrum. Emergence of CD49a+CD16CXCR3+ with lung homing capacity
48,49
Malaria Increased frequencies of activated NKp30+ cells across differentiation spectrum in CHIM with CD56dim subsets
dominating the responses. Emergence of CD38dimHLA-DR+CD45RO+ NK cells in sickle cell trait with low
parasitaemia. Role of HCMV co-infection not reported
60,61
Mycobacterium Enrichment of CD45RO+ NK cells in pleural effusions of pulmonary tuberculosis patients 64,65
SARS-CoV-2 Activation of CD56bright NK cells early in infection. High frequency and increased proliferation of
CD56dimNKG2C+Ksp37+ associated with disease severity. Adaptive expansions present in a higher proportion
of HCMV+ patients with severe COVID-19 compared to control or mild disease. Enrichment of CD56dimCD57+
NK cells in ARDS
74,78
Figure 1. Schematic summary of the natural killer cell differentiation pathway with potential points of interaction with different pathogens.
Many viral pathogens induce innate cytokines and type 1 interferons which activate and expand less differentiated CD56bright and CD56dimCD57
NK cells during early/acute infection. Viral pathogens also utilise direct mechanisms including via activating KIR-HLA interactions, in some cases
synergising with IL-15. HCMV promotes expansion of adaptive NK cells, forming a potential template for the role of persistent viral infections and
chronic or recurrent infections (e.g. by malaria parasites) to promote further expansion of adaptive NK cells and/or their terminal differentiation,
as defined by the loss of CD56 (CD56) and/or the expression of CD45RO.
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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short-lived, with reversal to pre-infection
characteristics during convalescence, compatible
with redistribution and regulation of the NK cell
response.49
The importance of infection in promoting
activation of relatively undifferentiated, tissue-
resident NK cells and migration to distinct
anatomical sites is also evident in recall responses
to VZV and hepatitis B viruses.50,51 NK cells with
characteristics of liver-resident NK cells
(CD56highCXCR6+CD16+NKG2D+CD69+CD62L+) were
enriched in skin blisters after challenge with VZV
skin test antigen,50 and CD49a+CD16 human liver
NK cells acquire epigenetic modifications and
migrate to the skin after hepatitis B vaccination.51
Hantavirus infection leads to rapid and
persistent in vivo expansion of NK cells across the
differentiation spectrum including CD57+NKG2C+
NK cells.52 Such expansions are associated with
elevated levels of IL-15 and with the Hantavirus-
driven upregulation of HLA-E on infected cells.
Furthermore, over 80% of infected individuals
were HCMV seropositive in the study, consistent
with the possibility that Hantavirus further
expands cells initially expanded by HCMV
infection.52 In this context, the activation of more
differentiated NK cells is supported by hantavirus-
induced upregulation of IL-15-IL-15R on epithelial
cells.53
Acute dengue virus infection is associated with
robust proliferation of all NK cell subsets,
irrespective of their differentiation status,
although CD56bright and CD56dimCD57 NK cells
dominate the response; this is associated with
increased IL-18 concentrations in plasma (and in
experimentally induced skin blister fluid) and
activation of IL-18-induced signalling pathways.54
In this case, the cells preferentially homing to the
skin were CD56bright and expressed a unique
combination of chemokine receptors, including
CLA-1 which is typically associated with skin
homing.54
Acute hepatitis C virus (HCV) infection leads to
increased blood frequencies of CD56bright cells, and
correspondingly decreased frequencies of CD56dim
NK cells, although both subsets of NK cells appear
activated.55 However, NK cell frequencies
subsequently normalised in patients who went on
to clear their infections and in those who
developed chronic infection and no long-term
impacts on NK cells were reported.55 Similarly,
another study reported increased frequencies of
CD56 NK cells and concomitantly reduced
frequencies of CD56dim, NKG2D+, NKp30+ and
NKp46+ NK cells during HCV infections.56
Importantly, frequencies of NKG2A+ and CD94+ NK
cells were increased in acute and chronic infection
but not in those whose infections resolved,
whereas frequencies of NKp30+, NKp46+ and
NKG2D+ cells were lower in those who resolved
their infections than in those who became
chronically infected.56 Consistent with these
observations, a recent study of HCMV seropositive
patients reported that high frequencies of
adaptive CD57+FceR1c NK cells and elevated
expression of PD-1 were associated with high viral
load in chronic HCV infection and were reduced
after direct-acting antiviral therapy (DAA).57 In a
separate study, chronic HCV infection was similarly
associated with higher frequencies of CD57+ and
PD-1+ NK cells compared to uninfected control
individuals.58 However, although PD1 expression
frequency reduced after DAA, proportions of
CD57+ and KLRG1+ cells increased after treatment,
suggesting ongoing expansion of highly
differentiated NK cells.58 The slightly different NK
cell outcomes in these two studies may be
explained by differences in HCMV status, HCV viral
genotype, viral load and treatment regimen.57,58
IMPACTS OF CHRONIC, PERSISTENT OR
RECURRENT INFECTION ON NK CELL
DIFFERENTIATION – EVIDENCE FROM
MALARIA AND TUBERCULOSIS
Human malaria infections provide insights into
the impacts of chronic and repeated infection on
the NK cell compartment. Blood stage malaria
parasites can induce high concentrations of
inflammatory and NK cell-activating cytokines
with associated NK cell activation seen in animal
models and human co-culture systems in vitro.59
Experimental, controlled human malaria infections
(CHMI) have given valuable insights into the
activation of NK cells during primary infection in
malaria-na€ıve individuals. Surprisingly, despite the
known role for inflammatory cytokines (IL-12, IL-
18) in activating less differentiated NK cells, the
primary acute response during CHMI is
characterised by activation (CD69 expression) of
NKp30+ NK cells distributed across the
differentiation spectrum but with CD56dim cells
dominating over CD56bright cells60; interestingly,
these expansions were closely linked to the course
of parasitaemia and resolved after treatment.60 It
is likely that both expansion and homing of
2021 | Vol. 10 | e1244
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activated CD56bright NK cells to – and their
retention in – secondary lymphoid tissues
contribute to redistribution of NK cell subsets
during active malaria infection.
The potential for chronic or repeated malaria
infections to influence NK cell phenotype and
function is illustrated by the identification of a
novel, activated CD38+HLADR+CD45RO+ NK cell
population in individuals with sickle cell trait who
have persistent low-density parasitaemia.61 A
possible explanation for this is that chronic
in vitro stimulation of NK cells via NKG2C in
combination with IL-15 induces CD45 isoform
switching on CD57+NKG2C+ cells, resulting in a
CD45RO+ population with high proliferative
potential, characteristic of central memory T
cells.14 Increased expression of checkpoint
inhibitors including TIM3 and PD-1 has also been
observed after repeated malaria exposure with
increasing age in endemic populations,62 again
with parallels to the emergence of LAG3 and PD1+
adaptive NK cells after activating receptor (NKp30,
NKG2D, NKG2C) or HCMV-mediated activation
in vitro.14 Interestingly, a CD25+CD45RO+ NK cell
population has been identified in patients with
metastatic melanoma treated with anti-PD-162,63
further supporting a potential for progressive
differentiation of NK cells in a manner analogous
to that seen in T cells. There is also evidence that
persistent Mycobacterium tuberculosis infections,
and the associated chronic inflammatory response,
lead to the emergence of CD45RO+ NK cells and
enrichment of these cells in the pleural effusion
fluid of pulmonary tuberculosis patients.64 These
cells are potent producers of both IL-22 and IFN-c
that are implicated, respectively, in tissue repair
and inflammation.65 Whether these NK cell
expansions rely on prior infection or co-infection
with other pathogens is unknown although there
is some evidence that the course of tuberculosis
can be modulated by HCMV co-infection.66,67
EMERGING PATHOGENS AND NK
CELLS
As described above, an abundance of
experimental and observational studies suggests a
role for infections, especially repeated or
persistent parasite or viral infections, in gradual
and extensive NK cell differentiation.
Furthermore, studies of emerging pathogens are
providing additional insights into the relative
impacts of innate and adaptive immune pathways
in inducing NK cell differentiation. Notably,
severe systemic inflammation is a hallmark of
severe Ebola and SARS-CoV-2 (COVID-19) disease;
this inflammation may in turn induce expansion
and differentiation of NK cells with potential
long-term consequences.
Ebola virus is an example of a novel pathogen
with only very limited adaptation to a human
host. Ebola virus-induced overproduction of the
NK cell-activating inflammatory cytokines IFN-a2
and IL-18, insufficiently counterbalanced by anti-
inflammatory cytokines (IL-10), is associated with
poor outcomes in Ebola virus disease (EVD).68
During EVD, there is a rapid reduction in the
frequency of CD56bright NK cells, within days of
infection, and a subsequent increase in the
frequencies of proliferating CD56bright and
CD56dim cells.69 In vitro, Ebola virus glycoprotein
directly induces the secretion of both pro-
inflammatory cytokines (including IL-18 which
contributes significantly to NK cell activation,
degranulation and IFN-c production) and anti-
inflammatory IL-10 (which restricts these
responses).70 In this scenario, NK cell responses are
dominated by CD56bright and CD56dimCD57 cells,
raising the possibility that these less
differentiated, cytokine-producing cells may act to
further amplify the inflammatory cascade (and
thus disease severity) in vivo. Interestingly,
increases in the frequency of CD56CD16+ NK cells
are observed up to 2 years after recovery from
severe EVD, suggestive of persistent activation
and/or terminal differentiation from
CD56dimCD16+ NK cells.47,71 However, in
experimental studies in mice, adoptive transfer of
dendritic cells exposed to virus-like particles
expressing the Ebola virus glycoprotein can prime
NK cells to protect against subsequent lethal
Ebola virus infection, raising the possibility that
NK cell activation by direct binding of a viral
ligand together with cytokine-mediated co-
stimulation could induce protective NK cell
effector mechanisms.72 Indeed, human NK cells
expressing NKp30 have been implicated in the
cytotoxic response to Ebola virus after interaction
with infected dendritic cells.73
More recently, NK cells have been implicated in
both protection against and pathogenesis of
SARS-CoV-2 infection (COVID-19). As in other viral
infections, and irrespective of outcome in terms of
disease, innate inflammatory pathways are
triggered early in SARS-CoV-2 infection. CD56bright
NK cells are activated, and their increased
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expression of perforin and granzyme B is
associated with inflammatory markers of disease
severity, in particular with high concentrations of
IL-6.74 In addition, reduced expression of CD16 on
CD56dim NK cells in people with COVID-1975 is
consistent with ongoing activation of this subset
by SARS-CoV-2 antigen/antibody immune
complexes.76 Importantly, HCMV infection and the
associated expansion of the subset of adaptive
CD56dimNKG2C+ NK cells were associated with
severe COVID-19. Over 90% of severe COVID-19
cases in this cohort were HCMV+ (compared with
~60% of controls and 80% of mild COVID-19
cases).74 More importantly, ~65% of people with
severe COVID-19 had expansion of adaptive NK
cells compared with only 10–20% of controls and
those with moderate disease.74 Whether these
expansions of adaptive NK cells in HCMV+ people
were driven by SARS-CoV-2, or whether they
predated SARS-CoV-2 infection, is not known but
these data do raise the possibility that adaptive
NK cells may contribute to tissue damage in
COVID-19. In support of this hypothesis, in COVID-
19 patients these adaptive cells also express
Ksp37, a marker of cytotoxic lymphocytes
associated with lung disease,77 and, despite their
lower intrinsic proliferative capacity, also express
markers of recent proliferation.74 This is
reminiscent of the increased proliferative capacity
of adaptive CD45RO+ NK cells in chronic malaria
infection as discussed above61,74 and is also
consistent with reports of enrichment of highly
differentiated CD56dimCD57+ NK cells with high
proliferative capacity in the peripheral blood in a
patient with SARS-CoV-2 infection and acute
respiratory distress syndrome (ARDS).78
A cluster of genes enriched in terminally
differentiated CD8+ T cells and CD56dimCD57+ NK
cells was downregulated in the blood of children
with multisystem inflammatory syndrome after
SARS-CoV-2 infection79 suggesting that there is no
straightforward relationship between NK cell
subset activation and disease severity. However, a
causal relationship between activation of highly
differentiated NK cells and severe COVID-19 is, as
yet, unproven and homing of less differentiated
CD56dim NK cells to the tissues during severe
disease may also contribute to alterations in cell
frequencies in peripheral blood.
The expansion of CD56dimNKG2C+ NK cells in
COVID-19 patients also raises the possibility that
increased expression of HLA-E in conjunction with
inflammatory mediators may mediate this
adaptive NK cell expansion.74 Indeed, a recent
study suggested that a peptide derived from the
SARS-CoV-2 spike 1 protein can stabilise HLA-E on
lung epithelial cells leading to activation of
NKG2C+ NK cells.80 Interestingly, an in silico study
also identified SARS-CoV-2 peptides predicted to
bind HLA-C alleles recognising activating KIR.81
VACCINATION AND NK CELLS
An indirect role for NK cells in regulating virus-
or vaccine-induced responses has been
highlighted in several experimental systems. For
example, NK cells have been shown to regulate
CD4+ T-cell responses and follicular T helper cell
(Tfh) activity, thereby influencing the breadth
and depth of the antibody response and effector
CD8+ T-cell response to vaccinia virus and LCMV
infections in murine models.82–84 Moreover,
adaptive/highly differentiated NK cells, which
express higher levels of the endosomal effector
protein RAB111FIP5, impact on the generation of
broadly neutralising antibodies in HIV-1-infected
individuals.85
However, mounting evidence also suggests that
NK cell differentiation is also affected by
vaccination (summarised in Table 2). Less
differentiated CD56bright and CD56dimCD57 NK
cells are activated after influenza virus
vaccination48,86,87 with evidence suggesting that
common c chain cytokines (IL-2, IL-12 and IL-15)
prime myeloid dendritic cells to secrete IL-12 to
support NK cell responses.88,89 Post-vaccination
increases in the frequencies of these less
differentiated CD56dimCD57 NK cells in HCMV+
individuals are consistent with IL-2 family
cytokines also supporting maintenance and
expansion of less differentiated, cytokine-
responsive subsets. However, more differentiated
CD56dimCD57+ cells are also enhanced post-
vaccination in the presence of influenza-specific
antibody rather than relying on cytokines for
their activation.76 In line with this, increased
frequencies of CD56dimCD16+NKG2C+ (CD57 and
CD57+) NK cells are observed up to 14 days after
seasonal influenza vaccination in individuals with
high titres of haemagglutination inhibiting
antibodies.90
A recent study demonstrated increased cytotoxic
and proliferative responses to antigen-pulsed
monocyte-derived dendritic cells by highly
differentiated CD56dimCD57+KLRG1+ NK cells after
hepatitis B subunit vaccination.91 Interestingly,
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these responses did not require the presence of
immune serum. Yellow fever vaccine 17D induces
proliferation and expansion of less differentiated
CD56bright and CD56dimCD57 NK cells; these cells
also demonstrate enhanced responsiveness to
in vitro restimulation with innate cytokines.92
Similarly, increased absolute numbers of
CD56bright and CD56dim NK cells are observed
within 3 days of immunisation with the rVSV-
ZEBOV Ebola virus vaccine; increased NK cell
expression of CXCR6 is an independent correlate
of rVSV-ZEBOV vaccine responsiveness whilst
reduced frequencies of NKG2D+ and increased
frequencies of NKp30 and KIR+ NK cells are
inversely correlated with plasma cytokine and
chemokine concentrations, indicating likely
recirculation of NK cell subsets within 72 h of
vaccination.93 The Ad26.ZEBOV Ebola virus vaccine
also activates CD56bright NK cells as assessed by the
induction of CD25 and Ki67 expression up to
14 days after the second dose.70 The extent to
which different vaccine vectors, delivery platforms
and adjuvating systems impact on NK cell
differentiation will likely depend on their primary
cellular tropism, interactions with pattern
recognition receptors and downstream production
of NK cell-activating cytokines; this aspect of
vaccination has as yet received very little
attention.
There are also many examples of potent, Fc
receptor-mediated degranulation and cytokine
production by more highly differentiated NK cells
in response to vaccination-induced antibody.76,94–96
Moreover, subunit, virally vectored and whole viral
vaccines, with or without chemical adjuvants, will
provide distinct cytokine signatures for co-
stimulation of NK cell responses with type 1
interferons, IL-15 and IL-18, all described to support
antibody-dependent responses of adaptive NK
cells.27,95,97,98 However, it is not known whether
these cytokine- and antibody-mediated signals
contribute to further differentiation of these
particular NK cells.
CONCLUSIONS
Exposure to an infection, be it in early life, with a
novel pathogen or after vaccination, is
accompanied by bystander, accessory-cell-
dependent proliferation and expansion of the ‘less
differentiated’ pool of NK cells. Cumulative
exposure to diverse pathogens, exacerbated by
chronic or recurrent infection, can lead to
progressive activation and expansion of ‘more
differentiated’ NK cells working in tandem with
the adaptive immune response. Cytokines from
antigen-specific T cells and pathogen-specific
antibodies amplify these NK cell responses, thereby
co-opting NK cells into the adaptive immune
response. Important questions remain, however, as
to how pathogens or vaccines influence NK cell
differentiation and functional diversification and
what this means for the ability of NK cells to then
contribute to protection from, or susceptibility to,
both infectious and non-communicable diseases.
Amongst these are the potential for maternal
antibodies to protect the infant from infection by
non-neutralising mechanisms and to induce NK cell
activation and differentiation in early life.
Differentiation of CD3CD16+ cells from cord blood
ILC1-like precursors provides an opportunity for
antibody-dependent effector cells to contribute to
immune responses, perhaps earlier in life than
hitherto appreciated. The extent to which NK cell
subsets re-equilibrate after a pathogen is
controlled or eliminated, and the mechanisms
whereby uncontrolled infections (e.g. Hantavirus,
severe SARS-CoV-2) or chronic or repeated
infections (e.g. hepatitis C and malaria) induce
lasting effects on the NK cell repertoire, are other
key issues that need further investigation
(Figure 1). The role, and the longer-term functional
Table 2. Impacts of vaccination on NK cell differentiation
Vaccine Impact on NK cell differentiation subset References
Ebola Increased absolute numbers of CD56bright and CD56dim NK subsets. Increased Ki67 and CD25 expression in
CD56bright NK cell
70,93
HBsAg Priming of CD56dimCD57+KLRG1+ NK cell subset revealed on in vitro restimulation 91
Influenza Activation, proliferation or expansion of CD56bright and CD56dimCD57 NK cells. Priming of CD56bright and
CD56dimCD57 NK cells for enhanced response to cytokines. Increased frequencies of CD56dimCD16+NKG2C+
(both CD57 and CD57+) NK cells in individuals with high HAI titres after vaccination
48,86,90
Yellow Fever Proliferation and expansion of CD56bright and CD56dimCD57 subsets 92
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consequences, of IL-15 in the expansion and
terminal differentiation of adaptive NK cells also
merits further investigation in the context of
different pathogens. In summary, individual
experiences of infection and vaccination over the
life course will shape not only the adaptive
immune cell population but also the NK cell
population, with consequences for susceptibility to
subsequent infections and, potentially, non-
communicable disease such as cancers as
inflammatory conditions.
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